30
Jan

San Francisco’s KaloBios is hitting the breaks on one of its lead programs after the asthma treatment missed its primary endpoint in a mid-stage trial, sending the company’s shares into a 30% tailspin.

…read more

Source: KaloBios calls it quits on its asthma drug after a Phase II flop

    

0 No comments